The PSA nadir that indicates potential cure after radiotherapy for prostate cancer

Urology

Volumn 49, Issue 3, 1997, Pages 322-326

  Critz, Frank A ^a,b   Levinson, A Keith ^a   Williams, W Hamilton ^a   Holladay, David A ^a   Holladay, Clinton T ^a  

^a Radiotherapy Clinics of Georgia   (United States)

^b 2349 Lawrenceville Highway ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT FAILURE; TREATMENT OUTCOME;

FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REMISSION INDUCTION;

EID: 0030887902     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00666-8     Document Type: Article

References (23)

1. Oesterling J, Tekchandani AH, Martin S, Bergstralh E, et al: The periurethral glands do not significantly influence the serum prostate specific antigen concentration. J Urol 155: 1658-1660, 1996.
2. Partin A, and Oesterling J: The clinical usefulness of prostate specific antigen: update 1994. J Urol 152: 1358-1368, 1994.
3. Takayama T, Vessella R, Brawer M, Noteboom J, and Lange P: The enhanced detection of persistent disease after prostatectomy with a new prostate specific antigen immunoassay. J Urol 150: 374-378, 1993.
4. Zagars G, and Pollack A: Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome. Urology 45: 476-483, 1995.
5. Stock RG, Stone NN, and DeWyngaert JK, et al: Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. CA Cancer J Clin 77: 2386-2392, 1996.
6. Schellhammer P, El-Mahdi AM, Wright GL, Kolm P, and Ragle R: Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate. Urology 42: 13-20, 1993.
7. Critz FA, Tarlton RS, and Holladay DA: Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. I-125 implant followed by external beam radiation. CA Cancer J Clin 75: 2383-2391, 1995.
8. Lee WR, Hanlon AL, and Hanks GE: Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease free survival. J Urol 156: 450-453, 1996.
9. Wallner K, Roy J, and Harrison L: Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol 14: 449-453, 1996.
10. Hanks G, Perez C, Kozar M, Asbell S, Pilepich M, and Pajak T: PSA conformation of cure at 10 years of T1B, T2, NO, MO prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation. Int J Radiat Oncol Biol Phys 30: 289-292, 1994.
11. Rosenzweig KE, Morgan WR, Lytton B, and Peschel RE: Prostate specific antigen following radiotherapy for local prostate cancer. J Urol 153: 1561-1564, 1995.
12. Stamey T, Ferrari M, and Schmid H: The value of serial prostate specific antigen determinations 5 years after radiotherapy: steep increasing values characterize 80% of patients. J Urol 150: 1856-1859, 1993.
13. Partin AW, Yoo J, Carter HB, et al: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150: 110-114, 1993.
14. Gehan EA: Estimating survival functions from the life table. J Chron Dis 21: 629-644, 1969.
15. Peto R, and Peto J: Asymptotically efficient rank invar-iant test procedures (with discussion). J R Stat Soc [A] 135: 185-206, 1972.
16. Zietman AL, Tibbs MK, Dallow KC, et al: Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiat Oncol 40: 159-162, 1996.
17. Kavadi V, Zagars G, and Pollack A: Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications. Int J Radiat Oncol Biol Phys 30: 279-287, 1994.
18. Goad J, Chang S, Ohori M, et al: PSA after definitive radiotherapy for clinically localized prostate cancer. Urol Clin North Am 20: 727-736, 1993.
19. Zietman AL, Coen JJ, Shipley WU, Willett CG, and Efird JT: Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 151: 640-645, 1994.
20. Partin A, Pound C, Clements J, et al: Serum PSA after anatomic radical prostatectomy. Urol Clin North Am 20: 713-725, 1995.
21. Trapasso J, deKernion J, Smith R, et al: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152: 1821-1825, 1994.
22. Frazier H, Robertson J, Humphrey P, et al: Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J Urol 149: 516-518, 1993.
23. Catalona W, and Smith D: 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 152: 1837-1842, 1994.